Search Results - "Nathan, F.E."

1274P First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227 by O'Byrne, K.J., Lee, K.H., Kim, S-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J-H., Daga, H., Yu, C-J., Hotta, K., Tanaka, H., Takeda, M., Yokoyama, T., Nathan, F.E., Lee, J-S.

Get full text

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis by Paz-Ares, L., Ciuleanu, T.E., Yu, X., Salman, P., Pluzanski, A., Nagrial, A., Havel, L., Kowalyszyn, R., Audigier-Valette, C., Wu, Y.-L., Borghaei, H., Hellmann, M.D., Brahmer, J., Reck, M., Ramalingam, S., Zhang, L., Bhagavatheeswaran, P., Nathan, F.E., O'Byrne, K.J.

Get full text

LBA4_PR - Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis by Peters, S., Ramalingam, S.S., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K.J., Geese, W.J., Bhagavatheeswaran, P., Nathan, F.E., Hellmann, M.D.

“…Part 1 of CheckMate 227 (NCT02477826), a phase III study in 1L NSCLC, has dual primary endpoints. The primary endpoint of progression-free survival (PFS) with…”
Get full text

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis by Peters, S., Ramalingam, S.S., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K.J., Geese, W.J., Bhagavatheeswaran, P., Nathan, F.E., Hellmann, M.D.

Get full text

CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) by Paz-Ares, L., Brahmer, J., Hellmann, M.D., Reck, M., O'Byrne, K., Borghaei, H., Geese, W.J., Lu, H., Nathan, F.E., Ramalingam, S.

Get full text

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer by Miller, K, Moul, J W, Gleave, M, Fizazi, K, Nelson, J B, Morris, T, Nathan, F E, McIntosh, S, Pemberton, K, Higano, C S

“…Background: Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC). This study, part of the…”
Get full text

The management of the shoulder skin microbiome (Cutibacterium acnes) in the context of shoulder surgery: a review of the current literature by Moore, Nathan FE, Batten, Timothy J, Hutton, Christopher EJ, White, William James, Smith, Christopher D

“…Background This review aims to establish current knowledge of the shoulder skin microbiome and how to manage the bacteria that reside within it. Methods A…”
Get full text

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial by Borghaei, H, O'Byrne, K J, Paz-Ares, L, Ciuleanu, T-E, Yu, X, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, R D, Valette, C A, Brahmer, J R, Reck, M, Ramalingam, S S, Zhang, L, Ntambwe, I, Rabindran, S K, Nathan, F E, Balli, D, Wu, Y-L

“…In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC)…”
Get full text

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients by O’Byrne, K.J., Lee, K.H., Kim, S.-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J.-H., Daga, H., Yu, C.-J., Hotta, K., Tanaka, H., Takeda, M., Yokoyama, T., Nathan, F.E., Lee, J.-S.

“…Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in efficacy versus chemotherapy with a manageable safety profile in patients with…”
Get full text

The male sling for stress urinary incontinence: urodynamic and subjective assessment by Ullrich, Nathan F E, Comiter, Craig V

“…We prospectively examined whether the fixed urethral resistance of the perineal male sling for the treatment of stress incontinence causes significant bladder…”
Get more information

The male sling for stress urinary incontinence: 24-month followup with questionnaire based assessment by Ullrich, Nathan F E, Comiter, Craig V

“…Stress urinary incontinence after prostate surgery can be a bothersome problem, adversely affecting quality of life. We performed a prospective study of the…”
Get more information

A technique of bladder neck closure combining prostatectomy and intestinal interposition for unsalvageable urethral disease by Ullrich, Nathan F E, Wessells, Hunter

“…We describe a technique of bladder neck detachment and augmented closure incorporating total prostatectomy and urinary diversion in men with complex bladder…”
Get more information

Adipose tissue fatty acid composition in humans with lipoprotein lipase deficiency by Ullrich, N F, Purnell, J Q, Brunzell, J D

“…Lipid stores in human adipose tissue are maintained primarily by incorporating lipid from circulating chylomicrons and very low density lipoproteins. Adipose…”
Get full text

Left Syringeal Dominance in Testosterone-Treated Female Canaries by Hartley, Rebecca Schurr, Chinn, Melissa S., Ullrich, Nathan F.E.

“…Male canaries (Serinus canaria) produce most of their song syllable types on the left side of the syrinx, the two-sided vocal organ. Female canaries treated…”
Get full text